Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively). Data from ZOE-50 and ZOE-70 trials were ana...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2018-03, Vol.36 (12), p.1537-1541 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1541 |
|---|---|
| container_issue | 12 |
| container_start_page | 1537 |
| container_title | Vaccine |
| container_volume | 36 |
| creator | Kovac, Martina Lal, Himal Cunningham, Anthony L. Levin, Myron J. Johnson, Robert W. Campora, Laura Volpi, Antonio Heineman, Thomas C. |
| description | An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).
Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.
In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged ≥50 years and 91.6% (43.3–99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.
HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229). |
| doi_str_mv | 10.1016/j.vaccine.2018.02.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2007121819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18302032</els_id><sourcerecordid>2007121819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-68bce95f2234ee13bf32b1f4d2fdb480b9babc47c419214af594458baa7d39ea3</originalsourceid><addsrcrecordid>eNqFkUuLFTEQhYMoznX0JygBN276mlc_4kaGi4-BATcK7kIe1TO5dCdtkh7RrX_cNPfqwo1QUIv66tThFELPKdlTQrvXx_29ttYH2DNChz1hteQDtKNDzxvW0uEh2hHWiUZQ8vUCPcn5SAhpOZWP0QWTouOC0R36dYjzMnmri48h4zjiO0gLZPwz5gIJ-4D9PK8h2spBgVBwnFwdaLdOJb_B18F6B8HChp4tYR0cXiZtwUR8m-K65G1avkc86XQLeLnTGTDHJXk95afo0VgbPDv3S_Tl_bvPh4_NzacP14erm8YKQUrTDcaCbEfGuACg3IycGToKx0ZnxECMNNpY0VtBJaNCj60Uoh2M1r3jEjS_RK9OukuK31bIRc0-W5gmHSCuWTFCesroQGVFX_6DHuOaQnVXKcravuUdqVR7omyKOScY1ZL8rNMPRYnavqSO6hzJtjYowmpt6i_O6quZwf3d-vOWCrw9AVDjuPeQVLZ-C9n5BLYoF_1_TvwGSIenqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2012575360</pqid></control><display><type>article</type><title>Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Kovac, Martina ; Lal, Himal ; Cunningham, Anthony L. ; Levin, Myron J. ; Johnson, Robert W. ; Campora, Laura ; Volpi, Antonio ; Heineman, Thomas C.</creator><creatorcontrib>Kovac, Martina ; Lal, Himal ; Cunningham, Anthony L. ; Levin, Myron J. ; Johnson, Robert W. ; Campora, Laura ; Volpi, Antonio ; Heineman, Thomas C. ; for the ZOE-50/70 Study Group ; ZOE-50/70 Study Group</creatorcontrib><description>An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).
Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.
In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged ≥50 years and 91.6% (43.3–99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.
HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.02.029</identifier><identifier>PMID: 29463421</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adults ; Age groups ; Clinical medicine ; Complications ; Confidence intervals ; Disease ; Effectiveness ; Herpes zoster ; Hospitalisation ; Hospitalization ; Immunocompetence ; Johnson, R W ; Mortality ; Neuralgia ; Older people ; Pain ; Population ; Postherpetic neuralgia ; Stroke ; Studies ; Vaccine efficacy ; Vaccines ; Varicella-zoster virus ; Vasculitis</subject><ispartof>Vaccine, 2018-03, Vol.36 (12), p.1537-1541</ispartof><rights>2018 The Author(s)</rights><rights>Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><rights>2018. The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-68bce95f2234ee13bf32b1f4d2fdb480b9babc47c419214af594458baa7d39ea3</citedby><cites>FETCH-LOGICAL-c440t-68bce95f2234ee13bf32b1f4d2fdb480b9babc47c419214af594458baa7d39ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2012575360?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29463421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovac, Martina</creatorcontrib><creatorcontrib>Lal, Himal</creatorcontrib><creatorcontrib>Cunningham, Anthony L.</creatorcontrib><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Johnson, Robert W.</creatorcontrib><creatorcontrib>Campora, Laura</creatorcontrib><creatorcontrib>Volpi, Antonio</creatorcontrib><creatorcontrib>Heineman, Thomas C.</creatorcontrib><creatorcontrib>for the ZOE-50/70 Study Group</creatorcontrib><creatorcontrib>ZOE-50/70 Study Group</creatorcontrib><title>Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).
Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.
In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged ≥50 years and 91.6% (43.3–99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.
HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).</description><subject>Adults</subject><subject>Age groups</subject><subject>Clinical medicine</subject><subject>Complications</subject><subject>Confidence intervals</subject><subject>Disease</subject><subject>Effectiveness</subject><subject>Herpes zoster</subject><subject>Hospitalisation</subject><subject>Hospitalization</subject><subject>Immunocompetence</subject><subject>Johnson, R W</subject><subject>Mortality</subject><subject>Neuralgia</subject><subject>Older people</subject><subject>Pain</subject><subject>Population</subject><subject>Postherpetic neuralgia</subject><subject>Stroke</subject><subject>Studies</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Varicella-zoster virus</subject><subject>Vasculitis</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUuLFTEQhYMoznX0JygBN276mlc_4kaGi4-BATcK7kIe1TO5dCdtkh7RrX_cNPfqwo1QUIv66tThFELPKdlTQrvXx_29ttYH2DNChz1hteQDtKNDzxvW0uEh2hHWiUZQ8vUCPcn5SAhpOZWP0QWTouOC0R36dYjzMnmri48h4zjiO0gLZPwz5gIJ-4D9PK8h2spBgVBwnFwdaLdOJb_B18F6B8HChp4tYR0cXiZtwUR8m-K65G1avkc86XQLeLnTGTDHJXk95afo0VgbPDv3S_Tl_bvPh4_NzacP14erm8YKQUrTDcaCbEfGuACg3IycGToKx0ZnxECMNNpY0VtBJaNCj60Uoh2M1r3jEjS_RK9OukuK31bIRc0-W5gmHSCuWTFCesroQGVFX_6DHuOaQnVXKcravuUdqVR7omyKOScY1ZL8rNMPRYnavqSO6hzJtjYowmpt6i_O6quZwf3d-vOWCrw9AVDjuPeQVLZ-C9n5BLYoF_1_TvwGSIenqg</recordid><startdate>20180314</startdate><enddate>20180314</enddate><creator>Kovac, Martina</creator><creator>Lal, Himal</creator><creator>Cunningham, Anthony L.</creator><creator>Levin, Myron J.</creator><creator>Johnson, Robert W.</creator><creator>Campora, Laura</creator><creator>Volpi, Antonio</creator><creator>Heineman, Thomas C.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180314</creationdate><title>Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials</title><author>Kovac, Martina ; Lal, Himal ; Cunningham, Anthony L. ; Levin, Myron J. ; Johnson, Robert W. ; Campora, Laura ; Volpi, Antonio ; Heineman, Thomas C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-68bce95f2234ee13bf32b1f4d2fdb480b9babc47c419214af594458baa7d39ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adults</topic><topic>Age groups</topic><topic>Clinical medicine</topic><topic>Complications</topic><topic>Confidence intervals</topic><topic>Disease</topic><topic>Effectiveness</topic><topic>Herpes zoster</topic><topic>Hospitalisation</topic><topic>Hospitalization</topic><topic>Immunocompetence</topic><topic>Johnson, R W</topic><topic>Mortality</topic><topic>Neuralgia</topic><topic>Older people</topic><topic>Pain</topic><topic>Population</topic><topic>Postherpetic neuralgia</topic><topic>Stroke</topic><topic>Studies</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Varicella-zoster virus</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovac, Martina</creatorcontrib><creatorcontrib>Lal, Himal</creatorcontrib><creatorcontrib>Cunningham, Anthony L.</creatorcontrib><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Johnson, Robert W.</creatorcontrib><creatorcontrib>Campora, Laura</creatorcontrib><creatorcontrib>Volpi, Antonio</creatorcontrib><creatorcontrib>Heineman, Thomas C.</creatorcontrib><creatorcontrib>for the ZOE-50/70 Study Group</creatorcontrib><creatorcontrib>ZOE-50/70 Study Group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovac, Martina</au><au>Lal, Himal</au><au>Cunningham, Anthony L.</au><au>Levin, Myron J.</au><au>Johnson, Robert W.</au><au>Campora, Laura</au><au>Volpi, Antonio</au><au>Heineman, Thomas C.</au><aucorp>for the ZOE-50/70 Study Group</aucorp><aucorp>ZOE-50/70 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2018-03-14</date><risdate>2018</risdate><volume>36</volume><issue>12</issue><spage>1537</spage><epage>1541</epage><pages>1537-1541</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).
Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.
In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged ≥50 years and 91.6% (43.3–99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.
HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29463421</pmid><doi>10.1016/j.vaccine.2018.02.029</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2018-03, Vol.36 (12), p.1537-1541 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2007121819 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Adults Age groups Clinical medicine Complications Confidence intervals Disease Effectiveness Herpes zoster Hospitalisation Hospitalization Immunocompetence Johnson, R W Mortality Neuralgia Older people Pain Population Postherpetic neuralgia Stroke Studies Vaccine efficacy Vaccines Varicella-zoster virus Vasculitis |
| title | Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T16%3A54%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complications%20of%20herpes%20zoster%20in%20immunocompetent%20older%20adults:%20Incidence%20in%20vaccine%20and%20placebo%20groups%20in%20two%20large%20phase%203%20trials&rft.jtitle=Vaccine&rft.au=Kovac,%20Martina&rft.aucorp=for%20the%20ZOE-50/70%20Study%20Group&rft.date=2018-03-14&rft.volume=36&rft.issue=12&rft.spage=1537&rft.epage=1541&rft.pages=1537-1541&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.02.029&rft_dat=%3Cproquest_cross%3E2007121819%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2012575360&rft_id=info:pmid/29463421&rft_els_id=S0264410X18302032&rfr_iscdi=true |